Recipharm Appoints New Position of Vice President Quality Management
News Mar 11, 2015
Recipharm has announced that it has appointed Thomas Beck to the new senior role of Vice President Quality Management (VP QM) with effect from 1st April 2015. Thomas is currently Head of Quality Control and Assurance at Recipharm Stockholm, a position that he has held since 2010. He is also Chairman of the Quality Assurance section within the Swedish Academy of Pharmaceutical Science.
In this new role Thomas will drive and coordinate the quality strategy and policy across the Recipharm Group subsidiaries and assist the Group Management Team (GMT) in monitoring and evaluating the company’s quality efforts. He will also lead the company’s audit process and support the sales activity by providing a primary contact point for new customers’ regulatory and quality affairs departments.
Reporting to the EVP Chief Operation Officer (COO) this post, represents an expansion of the Group Management Team (GMT) in a move designed to help it meet the increased demands the Group is facing following the recent rapid growth.
Commenting on the new appointment, Thomas Eldered, CEO of Recipharm, remarked: “This new position will bolster and enhance the work of the Group Management Team, meeting head on the quality management challenges our industry faces. Thomas will take a pivotal role in ensuring that we deliver and practice the highest standards of quality right across the entire Recipharm Group. He personally brings strong quality management expertise and already has specific experience of operations at Recipharm and the high standards that we are committed to delivering for our customers. I very much look forward to his authoritative support and direction being brought to bear for the benefit of the Group as a whole.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
New Research Hub to Tackle Global Vaccination ChallengesNews
The University of Bristol will contribute to a new research hub to increase global immunisation coverage and improve response to viral outbreaks through the rapid and cost-effective deployment of vaccines.READ MORE